FDA approved Abbvies risakizumab-rzaa (Skyrizi) as the 1st interleukin-23 inhibitor for use in adults with moderately to severely active Crohn's disease (600 mg IV at wk 0, 4, 8, &q8wk @ 360 mg SC). Approval based on ADVANCE, MOTIVATE & FORTIFY RCTs https://t.co/OMYNB1yr2R https://t.co/QMn9GWlYm9

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway? Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. https://t.co/SvkcZwqzBo https://t.co/M3BkoF4amb

Metanalysis of 7 studies shows that oral anticoagulants need not be discontinued for joint injections or aspiration. Only pts w/ hemorrhage after 5427 procedures, over 32-yrs. INR values of 3 bleeding cases was 1.9, 2.3, and 3.4. https://t.co/pCxDqzXGHQ https://t.co/ExZkXSliFo

Modest Benefits of Diet on Arthritis A EULAR taskforce reviewed the literature on the effects of diet and lifestyle behaviors in RMDs, and found little evidence suggesting dietary factors can substantially affect the outcomes in people with RMDs. https://t.co/D31l7dlq9v https://t.co/Kt80Yp74ro

Treatment of pyoderma gangrenosum is clinically empiric. Full read ref w/ Graded Rx Recommendations: - 1st line: Steriods or Cyclosporin - Consider biologics: TNFi, IL-1, IL-12/23, IL-17, IL-23 - Others: MTX, MMF, AZA, Dap, colchic, thalidomide, IVIG https://t.co/uMJyfFzsRB https://t.co/vw4VqbjZWh

Multinational recs. on Rx of JIA assoc. Uveitis: - Topical steroids are 1st line Rx - Systemic Rx if above fails or w/ poor prognosis or persistence - Options MTX, MMF then Humira EOW, then weekly ADA - Consider non-ETN TNFi's, then TCZ, ABA, JAKi or RTX https://t.co/ZfVeWf5sVg https://t.co/yu3to0LdEd

Podcast on Podcasting A tutorial on podcasting - what works and what does not. https://t.co/QINseXd6Z2 https://t.co/OFuVacgcfq

Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx

Axial PsA: Is it for Real? Dr. Janet Pope ( @Janetbirdope) presenting from EULAR 2022. https://t.co/0smaACel5k https://t.co/UJ3hi3rJlY

Lupus Research Alliance’s has awarded the Lupus Insight Prize to Akiko Iwasaki, PhD (professor at Yale School of Medicine) for her research on the pathogenic role of retroviruses in lupus published in Journal of Experimental Medicine https://t.co/xmQjFLk63K https://t.co/68Ezlfk00j

Lower Fx risk in PsA Rx w/ biologics? Review of 100 RCTs, 51,413 Pso & PsA pts; pts on bDMARDs had signif lower risk of major OP Fx (OR 0.34), hip Fx (OR 0.22) & OP non-vertebral Fx (OR 0.26). Fx risk not changed in RA, axSpA, SLE, IBD pts on biologics https://t.co/Acv1q1K5A9 https://t.co/dAaq2EsTDK